Efficacy and safety of risankizumab in patients with moderately to severely active Crohn’s disease: interim results from the SEQUENCE open-label extension study

Authors

John C. Chapman (ORCID: https://orcid.org/0000-0002-4130-2609)
W. Rachel Duan
Xiu Huang (ORCID: https://orcid.org/0000-0002-1368-4080)
Raja Atreya (ORCID: https://orcid.org/0000-0002-8556-8433)
Laurent Peyrin‐Biroulet (ORCID: https://orcid.org/0000-0003-2536-6618)
Silvio Danese (ORCID: https://orcid.org/0000-0001-7341-1351)
James O. Lindsay (ORCID: https://orcid.org/0000-0003-3353-9590)
Raymond Cross
Javier Zambrano (ORCID: https://orcid.org/0009-0005-3576-4435)
Stijn van Haaren
Toni Anschutz (ORCID: https://orcid.org/0009-0004-3594-5028)
Namita Joshi (ORCID: https://orcid.org/0000-0001-5577-2890)

Institutions

Mercy Medical Center (US)
Queen Mary University of London (GB)
Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
McGill University Health Centre (CA)
AbbVie (United States) (US)
Baton Rouge General (US)
IRCCS Ospedale San Raffaele (IT)
Nutrition-Génétique et Exposition aux Risques Environnementaux (FR)
Université de Lorraine (FR)

Publication Details

Journal: Journal of Crohn s and Colitis
Published: 2025-12-01
DOI: https://doi.org/10.1093/ecco-jcc/jjaf213
Citations: 1
Primary Topic: Inflammatory Bowel Disease
Type: article
Field-Weighted Citation Impact: 1.82

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Efficacy and safety of risankizumab in patients with moderately to severely active Crohn’s disease: interim results from the SEQUENCE open-label extension study

John C. Chapman, W. Rachel Duan, Xiu Huang, Raja Atreya et al.

Dec 1, 2025

1 citations

Journal of Crohn s and Colitis

Inflammatory Bowel Disease

1.82

article

Efficacy and safety of risankizumab in patients with moderately to severely active Crohn’s disease: interim results from the SEQUENCE open-label extension study

John C. Chapman, W. Rachel Duan, Xiu Huang, Raja Atreya, Laurent Peyrin‐Biroulet, Silvio Danese, James O. Lindsay, Raymond Cross, Javier Zambrano, Stijn van Haaren, Toni Anschutz, Namita Joshi

December 1, 2025article en

1 citations

Abstract

No abstract available for this paper.

Journal of Crohn s and ColitisVol. 19(12)

Mercy Medical Center (US), Queen Mary University of London (GB), Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), McGill University Health Centre (CA), AbbVie (United States) (US), Baton Rouge General (US), IRCCS Ospedale San Raffaele (IT), Nutrition-Génétique et Exposition aux Risques Environnementaux (FR), Université de Lorraine (FR)

Openalex Percentile: Top 11%

Inflammatory Bowel Disease

1.82

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Efficacy and safety of risankizumab in patients with moderately to severely active Crohn’s disease: interim results from the SEQUENCE open-label extension study — John C. Chapman, W. Rachel Duan, et al. · Journal of Crohn s and Colitis (2025) | TGRS Research Map | TGRS